Загрузка...
Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
The paradigm for managing patients with chronic myeloid leukemia is evolving. In the recent past, restoring a normal life expectancy while patients are receiving never-ending targeted therapy with BCR–ABL1 tyrosine kinase inhibitors through prevention of progression to blast phase and mitigation of...
Сохранить в:
| Опубликовано в: : | Hematology Am Soc Hematol Educ Program |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Hematology
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7727570/ https://ncbi.nlm.nih.gov/pubmed/33275744 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2020002538 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|